B-intervention	0	11	Abemaciclib
I-intervention	12	20	Combined
I-intervention	21	25	With
I-intervention	26	35	Endocrine
I-intervention	36	43	Therapy
O	44	47	for
O	48	51	the
O	52	60	Adjuvant
O	61	70	Treatment
O	71	73	of
O	74	76	HR
O	76	77	+
O	77	78	,
O	79	83	HER2
O	83	84	-
O	84	85	,
O	86	90	Node
O	90	91	-
O	91	99	Positive
O	99	100	,
O	101	105	High
O	105	106	-
O	106	110	Risk
O	110	111	,
O	112	117	Early
O	118	124	Breast
O	125	131	Cancer
O	132	133	(
O	133	141	monarchE
O	141	142	)
O	142	143	.

O	144	148	Many
O	149	157	patients
O	158	162	with
O	163	165	HR
O	165	166	+
O	166	167	,
O	168	172	HER2
O	172	173	-
O	174	179	early
O	180	186	breast
O	187	193	cancer
O	194	195	(
O	195	198	EBC
O	198	199	)
O	200	204	will
O	205	208	not
O	209	219	experience
O	220	230	recurrence
O	231	233	or
O	234	238	have
O	239	246	distant
O	247	257	recurrence
O	258	262	with
O	263	272	currently
O	273	282	available
O	283	291	standard
O	292	301	therapies
O	301	302	.

O	303	310	However
O	310	311	,
O	312	314	up
O	315	317	to
O	318	320	30
O	320	321	%
O	322	324	of
O	325	333	patients
O	334	338	with
O	339	343	high
O	343	344	-
O	344	348	risk
O	349	357	clinical
O	358	361	and
O	361	362	/
O	362	364	or
O	365	375	pathologic
O	376	384	features
O	385	388	may
O	389	399	experience
O	400	407	distant
O	408	418	recurrence
O	418	419	,
O	420	424	many
O	425	427	in
O	428	431	the
O	432	437	first
O	438	441	few
O	442	447	years
O	447	448	.

O	449	457	Superior
O	458	467	treatment
O	468	475	options
O	476	479	are
O	480	486	needed
O	487	489	to
O	490	497	prevent
O	498	503	early
O	504	514	recurrence
O	515	518	and
O	519	530	development
O	531	533	of
O	534	544	metastases
O	545	548	for
O	549	553	this
O	554	559	group
O	560	562	of
O	563	571	patients
O	571	572	.

O	573	584	Abemaciclib
O	585	587	is
O	588	590	an
O	591	595	oral
O	595	596	,
O	597	609	continuously
O	610	615	dosed
O	615	616	,
O	617	621	CDK4
O	621	622	/
O	622	623	6
O	624	633	inhibitor
O	634	642	approved
O	643	646	for
O	647	649	HR
O	649	650	+
O	650	651	,
O	652	656	HER2
O	656	657	-
O	658	666	advanced
O	667	673	breast
O	674	680	cancer
O	681	682	(
O	682	685	ABC
O	685	686	)
O	686	687	.

O	688	696	Efficacy
O	697	700	and
O	701	707	safety
O	708	710	of
O	711	722	abemaciclib
O	723	725	in
O	726	729	ABC
O	730	739	supported
O	740	750	evaluation
O	751	753	in
O	754	757	the
O	758	766	adjuvant
O	767	774	setting
O	774	775	.

O	776	780	This
O	781	785	open
O	785	786	-
O	786	791	label
O	791	792	,
O	793	798	phase
O	799	802	III
O	803	808	study
O	809	817	included
B-eligibility	818	826	patients
I-eligibility	827	831	with
I-eligibility	832	834	HR
I-eligibility	834	835	+
I-eligibility	835	836	,
I-eligibility	837	841	HER2
I-eligibility	841	842	-
I-eligibility	842	843	,
I-eligibility	844	848	high
I-eligibility	848	849	-
I-eligibility	849	853	risk
I-eligibility	854	857	EBC
I-eligibility	857	858	,
I-eligibility	859	862	who
I-eligibility	863	866	had
I-eligibility	867	874	surgery
I-eligibility	875	878	and
I-eligibility	878	879	,
I-eligibility	880	882	as
I-eligibility	883	892	indicated
I-eligibility	892	893	,
I-eligibility	894	906	radiotherapy
I-eligibility	907	910	and
I-eligibility	910	911	/
I-eligibility	911	913	or
I-eligibility	914	922	adjuvant
I-eligibility	922	923	/
I-eligibility	923	934	neoadjuvant
I-eligibility	935	947	chemotherapy
O	947	948	.

O	949	957	Patients
O	958	962	with
O	963	967	four
O	968	970	or
O	971	975	more
O	976	984	positive
O	985	990	nodes
O	990	991	,
O	992	994	or
O	995	998	one
O	999	1001	to
O	1002	1007	three
O	1008	1013	nodes
O	1014	1017	and
O	1018	1024	either
O	1025	1030	tumor
O	1031	1035	size
O	1036	1037	≥
O	1038	1039	5
O	1040	1042	cm
O	1042	1043	,
O	1044	1054	histologic
O	1055	1060	grade
O	1061	1062	3
O	1062	1063	,
O	1064	1066	or
O	1067	1074	central
O	1075	1077	Ki
O	1077	1078	-
O	1078	1080	67
O	1081	1082	≥
O	1083	1085	20
O	1085	1086	%
O	1086	1087	,
O	1088	1092	were
O	1093	1101	eligible
O	1102	1105	and
O	1106	1114	randomly
O	1115	1123	assigned
O	1124	1125	(
O	1125	1126	1
O	1126	1127	:
O	1127	1128	1
O	1128	1129	)
O	1130	1132	to
B-control	1133	1141	standard
I-control	1141	1142	-
I-control	1142	1144	of
I-control	1144	1145	-
I-control	1145	1149	care
O	1150	1158	adjuvant
O	1159	1168	endocrine
O	1169	1176	therapy
O	1177	1178	(
O	1178	1180	ET
O	1180	1181	)
O	1182	1186	with
O	1187	1189	or
O	1190	1197	without
O	1198	1209	abemaciclib
O	1210	1211	(
O	1211	1214	150
O	1215	1217	mg
O	1218	1223	twice
O	1224	1229	daily
O	1230	1233	for
O	1234	1235	2
O	1236	1241	years
O	1241	1242	)
O	1242	1243	.

O	1244	1247	The
O	1248	1255	primary
O	1256	1259	end
O	1260	1265	point
O	1266	1269	was
B-outcome-Measure	1270	1278	invasive
I-outcome-Measure	1279	1286	disease
I-outcome-Measure	1286	1287	-
I-outcome-Measure	1287	1291	free
I-outcome-Measure	1292	1300	survival
I-outcome-Measure	1301	1302	(
I-outcome-Measure	1302	1306	IDFS
I-outcome-Measure	1306	1307	)
I-outcome-Measure	1307	1308	,
O	1309	1312	and
O	1313	1322	secondary
O	1323	1326	end
O	1327	1333	points
O	1334	1342	included
B-outcome-Measure	1343	1350	distant
I-outcome-Measure	1351	1358	relapse
I-outcome-Measure	1358	1359	-
I-outcome-Measure	1359	1363	free
I-outcome-Measure	1364	1372	survival
O	1372	1373	,
B-outcome-Measure	1374	1381	overall
I-outcome-Measure	1382	1390	survival
O	1390	1391	,
O	1392	1395	and
B-outcome-Measure	1396	1402	safety
O	1402	1403	.

O	1404	1406	At
O	1407	1408	a
O	1409	1419	preplanned
O	1420	1428	efficacy
O	1429	1436	interim
O	1437	1445	analysis
O	1445	1446	,
O	1447	1452	among
B-total-participants	1453	1454	5
I-total-participants	1454	1455	,
I-total-participants	1455	1458	637
O	1459	1467	randomly
O	1468	1476	assigned
O	1477	1485	patients
O	1485	1486	,
O	1487	1490	323
B-outcome	1491	1495	IDFS
I-outcome	1496	1502	events
O	1503	1507	were
O	1508	1516	observed
O	1517	1519	in
O	1520	1523	the
O	1524	1530	intent
O	1530	1531	-
O	1531	1533	to
O	1533	1534	-
O	1534	1539	treat
O	1540	1550	population
O	1550	1551	.

O	1552	1563	Abemaciclib
O	1564	1568	plus
O	1569	1571	ET
O	1572	1584	demonstrated
O	1585	1593	superior
B-outcome	1594	1598	IDFS
O	1599	1605	versus
O	1606	1608	ET
O	1609	1614	alone
O	1615	1616	(
O	1616	1617	P
O	1618	1619	=
O	1620	1621	.
O	1621	1623	01
O	1623	1624	;
O	1625	1631	hazard
O	1632	1637	ratio
O	1637	1638	,
O	1639	1640	0
O	1640	1641	.
O	1641	1643	75
O	1643	1644	;
O	1645	1647	95
O	1647	1648	%
O	1649	1651	CI
O	1651	1652	,
O	1653	1654	0
O	1654	1655	.
O	1655	1657	60
O	1658	1660	to
O	1661	1662	0
O	1662	1663	.
O	1663	1665	93
O	1665	1666	)
O	1666	1667	,
O	1668	1672	with
B-outcome	1673	1674	2
I-outcome	1674	1675	-
I-outcome	1675	1679	year
I-outcome	1680	1684	IDFS
I-outcome	1685	1690	rates
O	1691	1693	of
B-iv-bin-percent	1694	1696	92
I-iv-bin-percent	1696	1697	.
I-iv-bin-percent	1697	1698	2
I-iv-bin-percent	1698	1699	%
O	1700	1706	versus
B-cv-bin-percent	1707	1709	88
I-cv-bin-percent	1709	1710	.
I-cv-bin-percent	1710	1711	7
I-cv-bin-percent	1711	1712	%
O	1712	1713	,
O	1714	1726	respectively
O	1726	1727	.

O	1728	1734	Safety
O	1735	1739	data
O	1740	1744	were
O	1745	1755	consistent
O	1756	1760	with
O	1761	1764	the
O	1765	1770	known
O	1771	1777	safety
O	1778	1785	profile
O	1786	1788	of
O	1789	1800	abemaciclib
O	1800	1801	.

O	1802	1813	Abemaciclib
O	1814	1818	when
O	1819	1827	combined
O	1828	1832	with
O	1833	1835	ET
O	1836	1838	is
O	1839	1842	the
O	1843	1848	first
O	1849	1853	CDK4
O	1853	1854	/
O	1854	1855	6
O	1856	1865	inhibitor
O	1866	1868	to
O	1869	1880	demonstrate
O	1881	1882	a
O	1883	1894	significant
O	1895	1906	improvement
O	1907	1909	in
O	1910	1914	IDFS
O	1915	1917	in
O	1918	1926	patients
O	1927	1931	with
O	1932	1934	HR
O	1934	1935	+
O	1935	1936	,
O	1937	1941	HER2
O	1941	1942	-
O	1943	1947	node
O	1947	1948	-
O	1948	1956	positive
O	1957	1960	EBC
O	1961	1963	at
O	1964	1968	high
O	1969	1973	risk
O	1974	1976	of
O	1977	1982	early
O	1983	1993	recurrence
O	1993	1994	.
